Inozyme Pharma Inc (INZY)
$5.83
+0.04
(+0.69%)▲
Performance
- $5.70$5.97$5.83
2.23%
Downside
Day's Volatility :4.52%
Upside
2.35%
- $2.69$7.80$5.83
53.86%
Downside
52 Weeks Volatility :65.51%
Upside
25.26%
Returns
| Period | Inozyme Pharma Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 30.41% | 6.5% | 0.0% |
6 Months | 22.93% | 7.1% | 0.0% |
1 Year | 5.27% | 9.8% | 0.0% |
3 Years | -69.84% | 14.2% | -20.2% |
Highlights
Market Capitalization | 352.6M |
Book Value | $1.92 |
Earnings Per Share (EPS) | -1.35 |
Wall Street Target Price | 19.43 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -32.56% |
Return On Equity TTM | -69.41% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -82.2M |
Diluted Eps TTM | -1.35 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.61 |
EPS Estimate Next Year | -1.57 |
EPS Estimate Current Quarter | -0.36 |
EPS Estimate Next Quarter | -0.36 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 233.28%
Technicals Summary
Sell
Neutral
Buy
Inozyme Pharma Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Inozyme Pharma Inc | 31.0% | 22.93% | 5.27% | -69.84% | -66.99% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Inozyme Pharma Inc | NA | NA | NA | -1.61 | -0.69 | -0.33 | NA | 1.92 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Inozyme Pharma Inc | Buy | $352.6M | -66.99% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Inozyme Pharma Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 56.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 256.3%
Institutional Holdings
Adage Capital Partners Gp LLC
8.62%Pivotal bioVenture Partners Investment Advisor LLC
7.27%Sofinnova Ventures
6.92%Rock Springs Capital Management LP
5.95%Eventide Asset Management, LLC
5.14%BlackRock Inc
4.99%
Company Information
we are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. our area of expertise is in disorders of paradoxical mineralization and our lead drug is an enzyme replacement therapy in pre-clinical development.
Organization | Inozyme Pharma Inc |
Employees | 59 |
CEO | Dr. Douglas A. Treco Ph.D. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$5.83
+0.69%
Keyarch Acquisition Corp
$5.83
+0.69%
Connexa Sports Technologies Inc
$5.83
+0.69%
Us Value Etf
$5.83
+0.69%
First Wave Biopharma Inc
$5.83
+0.69%
Global X Msci Next Emerging
$5.83
+0.69%
Fat Projects Acquisition Corp
$5.83
+0.69%
Capital Link Global Fintech
$5.83
+0.69%
Applied Uv Inc
$5.83
+0.69%